Lansoprazole Viatris (Lansoprazole)

The drug works by irreversibly inhibiting the H+/K+ ATPase enzyme, also known as the gastric proton pump, in the parietal cells of the stomach. This blockade prevents the final step of acid secretion, leading to a sustained reduction in gastric acidity.

The appropriate dose of Lansoprazole Viatris is determined by the prescribing clinician based on the specific indication, patient age, renal and hepatic function, and response to therapy. Typical adult regimens range from 15 mg to 30 mg once daily, but exact dosing must follow the prescriber’s order.

Safety data for Lansoprazole during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus. Women who are breastfeeding should consult their healthcare provider, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lansoprazole belongs to the same class as omeprazole, esomeprazole, pantoprazole and rabeprazole. All PPIs share a similar mechanism of inhibiting the gastric proton pump, but differences exist in pharmacokinetic profiles, potency, and drug‑interaction potential. Clinicians may choose Lansoprazole based on individual patient response, dosing convenience, or specific interaction considerations.

Lansoprazole tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Lansoprazole is taken orally, usually as a whole tablet swallowed with a glass of water. It is generally recommended to take the medication before a meal, often in the morning, unless the prescriber advises a different schedule.

Serious but rare risks include Clostridioides difficile‑associated diarrhea, acute interstitial nephritis, severe hepatic injury, and an increased risk of bone fractures with long‑term use. Patients should be monitored for signs of infection, renal or liver dysfunction, and unexplained bone pain.

Individuals with a known hypersensitivity to Lansoprazole or any other proton pump inhibitor should avoid the drug. Caution is also advised for patients with severe liver disease, those taking medications that have major interactions (e.g., clopidogrel), and patients who are pregnant or breastfeeding unless clearly indicated by a healthcare professional.